Dosage ; Moderate risk: 20mg, 1-2hours before surgery then 20mg OD for 7-10 days. High risk: 40mg 12hours before surgery then 40mg OD for 7-10 days.
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Clexane | Sanofi Aventis | Surgipharm Ltd | 20mg | 2 | Injection | per vial | KES 952.00 |
| Clexane | Sanofi Aventis | Surgipharm Ltd | 40mg | 2 | Injection | per vial | KES 1,538.00 |
| Clexane | Sanofi Aventis | Surgipharm Ltd | 40mg | 10 | Injection | per vial | KES 7,255.00 |
| Clexane | Sanofi Aventis | Surgipharm Ltd | 60mg | 10 | Injection | per vial | KES 9,758.00 |
| Clexane | Sanofi Aventis | Surgipharm Ltd | 60mg | 2 | Injection | per vial | KES 2,087.00 |
| Clexane | Sanofi Aventis | Surgipharm Ltd | 80mg | 2 | Injection | per vial | KES 3,057.00 |
| Clexane | Sanofi Aventis | Surgipharm Ltd | 80mg | 10 | Injection | per vial | KES 14,331.00 |
| Lomoh | Emcure Pharmaceuticals Limited | Syner-Medica (K) Ltd | 40mg | 1 | Injection | per vial | KES 440.00 |
| Lomoh | Emcure Pharmaceuticals Limited | Syner-Medica (K) Ltd | 60mg | 1 | Injection | per vial | KES 510.00 |
| Parin-E | Venus Remedies Limited | Surgipharm Ltd | 20mg | 2 | Injection | per vial | KES 900.00 |
| Parin-E | Venus Remedies Limited | Surgipharm Ltd | 40mg | 2 | Injection | per vial | KES 1,057.00 |
| Parin-E | Venus Remedies Limited | Surgipharm Ltd | 60mg | 2 | Injection | per vial | KES 1,600.00 |
| Enoxaparin More info | |
|---|---|
| Mode Of Action | Heparin interacts with anti-thrombin III heparin cofactor to produce a substance that immediately neutralizes thrombin by forming a complex with it at its active serine center. It also inhibits platelet function, increases the permeability of vessel walls, inhibits the proliferation of vascular smooth muscle cells, inhibits delayed hypersensitivity reactions, and is involved in the regulation of angiogenesis. |
| Drug Indication | Prophylaxis of post-operation venous thrombosis and embolism in high risk patients. |
| Precautions | Hepatic impairment, renal impairment, not to be used interchangeably with other low molecular weight heparins, patients with induced thrombocytopenia, standard clotting time not useful in monitoring treatment. |
| Contra-Indications | Patients at high risk of haemorrhage, heparin and its derivatives, peptic ulcer, severe hypertension, hypersensitivity to heparin, hepato-renal failure, thrombocytopenia. |
| Dosage | Moderate risk: 20mg, 1-2hours before surgery then 20mg OD for 7-10 days. High risk: 40mg 12hours before surgery then 40mg OD for 7-10 days. |
| Special Information | Low-molecular-weight heparins with an average molecular weight of 4000 to 6500 daltons. They have an attenuated effect on coagulation and prolongation of the activated partial thromboplastin time compared with unfractionated heparin. |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |
| Drug Sub-Category | Low molecular heparin |